Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications.
Bacillus Calmette-Guerin
bladder cancer
genomic subtypes
immunosurveillance
tumor microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
08
2019
accepted:
04
11
2019
entrez:
12
12
2019
pubmed:
12
12
2019
medline:
12
12
2019
Statut:
epublish
Résumé
Immunosurveillance, which describes the immunologically mediated elimination of transformed cells, has been widely accepted in the context of bladder cancer for many decades with the successful use of Bacillus-Calmette Guerin for superficial bladder cancer since the 1970s. With the emergence of checkpoint inhibitor blockade in the treatment of urothelial cancers, there has been a resurgent interest in the immunology of bladder cancer. The theory of cancer immunoediting proposes that the immune system has both pro-tumorigenic and anti-tumor effects, the balance between the two determining the progression of an individual tumor. However, whilst there is evidence for the action of various immune cell populations in bladder cancer, a cohesive picture of the immune response to bladder cancer and its driving forces are still lacking. Additionally, little is still known about the normal immune landscape of the bladder. Future progress in bladder cancer therapeutic approaches will require a strong foundation in understanding the immunology of this disease. This review considers the evidence for the role of the main immune cell populations, both innate and adaptive, in the immune response to bladder cancer. Recent research and overarching themes in the immune response to bladder cancer are explored. The minimal evidence regarding the normal immune landscape of the human bladder is also summarized to contextualize downstream immune responses. Of specific interest are the innate and myeloid populations, some of which are resident in the human bladder and which have significant effects on downstream adaptive tumor immunity. We discuss factors which restrain the efficacy of populations known to have anti-tumor activity such as cytotoxic T cells, including the constraints on checkpoint blockade. Additionally, the effects on the immune response of tumor intrinsic factors such as the genomic subtype of bladder cancer and the effect of common therapies such as chemotherapy and intravesical Bacillus Calmette-Guerin are considered. A significant theme is the polarization of immune responses within the tumor by a heavily immunosuppressive tumor microenvironment which affects the phenotype of multiple innate and adaptive populations. Throughout, clinical implications are discussed with suggestions for future research directions and therapeutic targeting.
Identifiants
pubmed: 31824850
doi: 10.3389/fonc.2019.01270
pmc: PMC6879653
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1270Informations de copyright
Copyright © 2019 Joseph and Enting.
Références
Clin Exp Immunol. 1992 Mar;87(3):450-4
pubmed: 1544229
Oncotarget. 2015 Dec 15;6(40):43081-9
pubmed: 26517808
J Urol. 2009 Apr;181(4):1571-80
pubmed: 19230924
Cytokine. 2003 Jan 7;21(1):17-26
pubmed: 12668155
Int J Cancer. 2012 Mar 1;130(5):1109-19
pubmed: 21480223
BJU Int. 2004 Dec;94(9):1377-83
pubmed: 15610124
Adv Immunol. 2006;90:1-50
pubmed: 16730260
Br J Urol. 1986 Feb;58(1):19-25
pubmed: 2936415
Urology. 2015 Mar;85(3):703.e1-6
pubmed: 25733301
Annu Rev Pathol. 2016 May 23;11:149-74
pubmed: 26907529
Cancer Res. 2000 Apr 15;60(8):2290-9
pubmed: 10786697
Clin Exp Immunol. 2018 Oct;194(1):39-53
pubmed: 30009527
Oncotarget. 2017 Jun 13;8(24):38378-38388
pubmed: 28418913
Mol Oncol. 2014 May;8(3):753-65
pubmed: 24656965
Cancer Immunol Immunother. 2010 Mar;59(3):465-72
pubmed: 19756593
Br Med Bull. 2018 Dec 1;128(1):5-14
pubmed: 30137312
J Urol. 2009 Apr;181(4):1894-900
pubmed: 19237175
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
J Exp Med. 2009 Jul 6;206(7):1457-64
pubmed: 19564351
Urol Oncol. 2008 Jul-Aug;26(4):341-5
pubmed: 18593617
JCI Insight. 2018 Dec 6;3(23):
pubmed: 30518683
Oncoimmunology. 2013 Dec 1;2(12):e26860
pubmed: 24498559
Urologia. 2014 Oct-Dec;81(4):233-6
pubmed: 24803354
J Clin Invest. 2017 Aug 1;127(8):2916-2929
pubmed: 28650339
Cancer Metastasis Rev. 2009 Dec;28(3-4):345-53
pubmed: 19967427
J Urol. 1999 Jun;161(6):1962-7
pubmed: 10332481
Clin Genitourin Cancer. 2016 Dec;14(6):473-484
pubmed: 27209348
Cancer. 1995 May 15;75(10):2565-70
pubmed: 7736402
Cancer Res. 2006 Aug 15;66(16):8250-7
pubmed: 16912205
Nat Immunol. 2019 Feb;20(2):218-231
pubmed: 30643268
J Clin Lab Anal. 2012 Sep;26(5):365-71
pubmed: 23001982
Clin Immunol. 2018 Aug;193:60-69
pubmed: 29410331
Clin Exp Immunol. 2001 Dec;126(3):397-402
pubmed: 11737053
Oncoimmunology. 2016 Feb 18;5(5):e1134412
pubmed: 27467953
Clin Cancer Res. 2018 Jul 1;24(13):3069-3078
pubmed: 29514839
Cancer Immunol Immunother. 2009 Aug;58(8):1245-55
pubmed: 19139883
Int J Urol. 1997 Jan;4(1):68-73
pubmed: 9179670
Urology. 2003 Jul;62(1):162-6
pubmed: 12837459
Clin Transl Oncol. 2019 Apr;21(4):391-403
pubmed: 30291519
Eur Urol. 2020 Apr;77(4):420-433
pubmed: 31563503
Nat Commun. 2018 Sep 20;9(1):3826
pubmed: 30237493
Cancer Manag Res. 2019 Apr 12;11:2987-2995
pubmed: 31114346
Cancer Invest. 2018;36(7):395-405
pubmed: 30199269
Arch Ital Urol Androl. 2013 Dec 31;85(4):157-63
pubmed: 24399114
Int J Urol. 2007 Jun;14(6):532-8; discussion 538
pubmed: 17593099
Br J Urol. 1994 May;73(5):508-15
pubmed: 8012772
Int J Urol. 2000 Jul;7(7):263-9
pubmed: 10910229
J Urol. 2007 Jan;177(1):353-8
pubmed: 17162090
Front Immunol. 2013 Jul 11;4:190
pubmed: 23874336
PLoS One. 2018 Sep 27;13(9):e0204745
pubmed: 30261082
Oncotarget. 2018 Nov 23;9(92):36492-36502
pubmed: 30559932
Int J Cancer. 1979 Apr 15;23(4):487-93
pubmed: 86524
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Br J Cancer. 1990 Oct;62(4):603-6
pubmed: 1699592
Oncol Lett. 2018 Sep;16(3):2851-2856
pubmed: 30127871
Pathol Res Pract. 2018 Aug;214(8):1074-1080
pubmed: 29803657
J Urol. 1977 Jul;118(1 Pt 1):2-6
pubmed: 327096
Front Immunol. 2015 Jun 08;6:284
pubmed: 26106390
Br J Urol. 1991 Nov;68(5):473-8
pubmed: 1720992
Front Immunol. 2019 Mar 29;10:622
pubmed: 30984190
FEBS J. 2018 Dec;285(23):4316-4342
pubmed: 29851227
Oncogene. 2017 Apr;36(15):2095-2104
pubmed: 27721403
Clin Exp Immunol. 2010 Sep;161(3):480-9
pubmed: 20646003
J Pathol. 2019 Oct;249(2):151-165
pubmed: 31102277
Cancer Immunol Res. 2018 May;6(5):528-538
pubmed: 29588320
J Urol. 1998 Jun;159(6):2185-92
pubmed: 9598567
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Oncotarget. 2016 Mar 22;7(12):13765-81
pubmed: 26871598
Urol Oncol. 2018 Sep;36(9):405-412
pubmed: 29606341
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Cancer Immunol Immunother. 2009 Apr;58(4):493-502
pubmed: 18682944
Chin Med J (Engl). 2012 Apr;125(7):1254-60
pubmed: 22613597
Cancer Immunol Res. 2017 Jul;5(7):594-603
pubmed: 28588015
Lancet Oncol. 2017 Jun;18(6):e341-e353
pubmed: 28593860
Oncol Lett. 2016 May;11(5):3403-3408
pubmed: 27123124
J Investig Dermatol Symp Proc. 2004 Jan;9(1):5-14
pubmed: 14870978
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
BJU Int. 2001 Oct;88(6):602-10
pubmed: 11678759
Immunology. 2018 Apr 27;:
pubmed: 29700809
Urol Oncol. 2011 Jan-Feb;29(1):58-65
pubmed: 19837616
Oncol Rep. 2019 Aug;42(2):581-594
pubmed: 31233191
PLoS One. 2018 Jul 2;13(7):e0200079
pubmed: 29966014
Eur J Immunol. 2011 Jan;41(1):246-51
pubmed: 21182095
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
Oncotarget. 2017 Jan 24;8(4):7175-7180
pubmed: 27764780
Cancer Res. 2004 May 15;64(10):3386-90
pubmed: 15150089
Eur Urol. 2019 Apr;75(4):637-646
pubmed: 30655087
BJU Int. 2011 Nov;108(10):1672-8
pubmed: 21244603
Cancer Treat Rev. 2017 Mar;54:58-67
pubmed: 28214651
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11510-6
pubmed: 26617883
World J Urol. 2016 Feb;34(2):181-7
pubmed: 26055646
J Exp Med. 2018 Nov 5;215(11):2748-2759
pubmed: 30257862
PLoS Pathog. 2015 Jul 16;11(7):e1005044
pubmed: 26182347
Expert Rev Anticancer Ther. 2015 May;15(5):509-23
pubmed: 25882710
J Urol. 1976 Aug;116(2):180-3
pubmed: 820877
Eur Urol Focus. 2016 Oct;2(4):445-452
pubmed: 28723478
Cell Death Dis. 2019 Jan 18;10(2):50
pubmed: 30718502
Clin Epigenetics. 2018 Aug 3;10(1):102
pubmed: 30075815
Int J Oncol. 1997 Feb;10(2):387-93
pubmed: 21533389
Hum Pathol. 2013 Aug;44(8):1630-7
pubmed: 23574787
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Cell Biol Int. 2017 Feb;41(2):177-186
pubmed: 27987237
Int J Mol Sci. 2017 Oct 19;18(10):
pubmed: 29048388
Int J Cancer. 2001 Jun 1;92(5):697-702
pubmed: 11340575
Cancer Sci. 2019 Feb;110(2):489-498
pubmed: 30548363
Arch Surg. 2012 Apr;147(4):366-72
pubmed: 22508783
Urol Oncol. 2014 Aug;32(6):791-7
pubmed: 24794251
Urol Oncol. 2018 Sep;36(9):389-399
pubmed: 29884342
Clin Cancer Res. 2017 Dec 1;23(23):7388-7399
pubmed: 28928159
Front Immunol. 2013 Jun 27;4:169
pubmed: 23818888
Nat Rev Urol. 2018 Oct;15(10):615-625
pubmed: 29991725
Eur J Cancer. 2015 Nov;51(17):2655-64
pubmed: 26338196